{"id":11092,"date":"2023-06-22T00:00:00","date_gmt":"2023-06-22T05:00:00","guid":{"rendered":"https:\/\/myeloma.ca\/1970\/01\/01\/une-analyse-de-sang-destinee-a-la-surveillance-du-myelome-multiple-a-ete-homologuee-pour-un-usage-clinique-aux-etats-unis-en-anglais-seulement\/"},"modified":"2025-08-19T08:28:10","modified_gmt":"2025-08-19T13:28:10","slug":"une-analyse-de-sang-destinee-a-la-surveillance-du-myelome-multiple-a-ete-homologuee-pour-un-usage-clinique-aux-etats-unis-en-anglais-seulement","status":"publish","type":"post","link":"https:\/\/myeloma.ca\/fr\/2023\/06\/22\/une-analyse-de-sang-destinee-a-la-surveillance-du-myelome-multiple-a-ete-homologuee-pour-un-usage-clinique-aux-etats-unis-en-anglais-seulement\/","title":{"rendered":"UNE ANALYSE DE SANG DESTIN\u00c9E \u00c0 LA SURVEILLANCE DU MY\u00c9LOME MULTIPLE A \u00c9T\u00c9 HOMOLOGU\u00c9E POUR UN USAGE CLINIQUE AUX \u00c9TATS-UNIS (EN ANGLAIS SEULEMENT)"},"content":{"rendered":"

Rapid Novor Inc., the world\u2019s leader in mass spectrometry (MS)-based antibody protein sequencing, announced today that its diagnostic laboratory obtained the Clinical Laboratory Improvement Amendments (CLIA) certification for their EasyM\u2122 assay as a Laboratory Developed Test (LDT). EasyM\u2122 is the world\u2019s first personalized blood test for Multiple Myeloma to receive such certification. This means clinicians now have access to a simple blood test for highly sensitive measurable residual disease (MRD) monitoring of multiple myeloma.<\/em><\/p>\n

Multiple myeloma is the second most common form of hematological (blood) cancer with ~175,000 new cases worldwide each year. The presence of MRD is an important prognostic factor for multiple myeloma and typically requires ongoing assessments for detection and monitoring of disease progression. However, current clinical tests for MRD often lack the sensitivity or require the invasive, expensive, and time-intensive practice of bone marrow biopsies \u2013 putting physical and financial burden on the patients.<\/em><\/p>\n

\u201cThe CLIA certification for EasyM\u2122 is a major milestone in multiple myeloma MRD testing,\u201d said Dr. Liqiang Yang, Chief Strategy Officer at Rapid Novor. \u201cEasyM\u2122 now provides a much-needed option for patients with multiple myeloma who can benefit from frequent monitoring of their disease especially during the complete remission (CR) stage without invasive bone-marrow aspirates. The non-invasive and highly sensitive nature of EasyM\u2122 makes it an ideal assay to assess MRD status as an efficacy endpoint for clinical trials of novel therapeutic drugs.\u201d<\/em><\/p>\n

The EasyM\u2122 assay measures the levels of M-protein, a well-known biomarker for multiple myeloma, using Rapid Novor\u2019s proprietary MS-based protein sequencing technology. EasyM\u2122 can improve the way the disease is monitored to foster informed decisions on potential therapies and treatment regimens. Data from retrospective clinical studies suggest that EasyM\u2122 could provide earlier predictions of relapse compared to conventional methods.<\/em><\/p>\n

The CLIA certification of Rapid Novor\u2019s Diagnostic Laboratory means that patients in the US diagnosed with multiple myeloma will now be able to access EasyM\u2122 as a clinical testing option for enhanced disease monitoring. Rapid Novor is currently in the process of obtaining certification of the EasyM\u2122 assay within Canada to bring this non-invasive, sensitive, clinical test to Canadian patients with multiple myeloma.<\/em><\/p>\n

About Rapid Novor Diagnostic Laboratory
\nRapid Novor Diagnostic Laboratory is a business unit of Rapid Novor Inc.<\/em><\/p>\n

For more information, click here<\/a>.About Rapid Novor Inc.<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"

Rapid Novor Inc., the world\u2019s leader in mass spectrometry (MS)-based antibody protein sequencing, announced today that its diagnostic laboratory obtained the Clinical Laboratory Improvement Amendments (CLIA) certification for their EasyM\u2122 assay as a Laboratory Developed Test (LDT). EasyM\u2122 is the world\u2019s first personalized blood test for Multiple Myeloma to receive such certification. This means clinicians […]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[53,50,58,52],"tags":[],"class_list":["post-11092","post","type-post","status-publish","format-standard","hentry","category-actualites-et-evenement","category-news-events","category-nouvelles-de-myelome-canada","category-whats-new-at-myeloma-canada"],"acf":[],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts\/11092","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/comments?post=11092"}],"version-history":[{"count":1,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts\/11092\/revisions"}],"predecessor-version":[{"id":31257,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts\/11092\/revisions\/31257"}],"wp:attachment":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/media?parent=11092"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/categories?post=11092"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/tags?post=11092"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}